Your browser doesn't support javascript.
loading
Vaccines, Antibodies and Donors: Varying Attitudes and Policies Surrounding COVID-19 and Heart Transplantation.
Defilippis, Ersilia M; Allen, Larry A; Bhatt, Ankeet S; Joseph, Susan; Kittleson, Michelle; Vardeny, Orly; Drazner, Mark H; Lala, Anuradha.
Afiliação
  • Defilippis EM; Division of Cardiology, Columbia University Irving Medical Center, New York, New York.
  • Allen LA; Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado.
  • Bhatt AS; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Joseph S; Department of Cardiology, University of Maryland Medical Center, Baltimore, Maryland.
  • Kittleson M; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Vardeny O; Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, and University of Minnesota, Minneapolis, Minnesota.
  • Drazner MH; Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Lala A; Zena and Michael A. Wiener Cardiovascular Institute & Department of Population Health Science, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: anu.lala@mountsinai.org.
J Card Fail ; 28(12): 1727-1732, 2022 12.
Article em En | MEDLINE | ID: mdl-35718306
INTRODUCTION: There are varied opinions in the United States regarding many aspects of care related to COVID-19. The purpose of this study was to examine the opinions of health care personnel and the policies of heart transplant centers concerning practices for the prevention and treatment of COVID-19 in donors and recipients of heart transplants. METHODS: Two anonymous, electronic web-based surveys were developed: 1 was administered to health care personnel through a mailing list maintained by the Heart Failure Society of America (HFSA); another was administered to U.S. medical adult and pediatric heart transplant (HT) program directors. Individual and group e-mails were sent with an embedded link to the respective surveys in February 2022. RESULTS: A total of 176 individuals (8.6%) responded to the survey administered through the HFSA. Of medical directors of transplant programs, 78 (54% response rate) completed a separate survey on their centers' policies. Although 95% (n = 167) of individuals indicated vaccination against COVID-19 should be required prior to HT, only 67% (n = 52) of centers mandated that practice. Similarly, 61% of individuals thought vaccination should be required prior to HT for caregivers, but only 13% of transplant centers mandated caregiver vaccination. Of the centers, 63% reported considering donors despite histories of recent COVID-19 infection (within 3 months), and 47% considered donors with current positive polymerase chain reaction tests. Regarding post-transplant care, only 22% of programs routinely measured antibodies to COVID-19, and 71% used tixagevimab/cilgavimab (Evusheld) for pre-exposure prophylaxis. CONCLUSIONS: There were significant differences between individual preferences and centers' practices with respect to COVID-19 management of candidates for and recipients of HT. Additionally, there was wide variation in policies among centers, reflecting the need for further study to inform consistent guidance and recommendations across centers to optimize equitable care for this high-risk patient population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Transplante de Coração / COVID-19 / Insuficiência Cardíaca Tipo de estudo: Guideline Limite: Child / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Transplante de Coração / COVID-19 / Insuficiência Cardíaca Tipo de estudo: Guideline Limite: Child / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article